X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (149) 149
index medicus (145) 145
daily intravenous busulfan (142) 142
hematology (130) 130
transplantation (124) 124
male (107) 107
female (105) 105
bone-marrow-transplantation (98) 98
adult (97) 97
immunology (94) 94
middle aged (91) 91
busulfan (88) 88
busulfan - administration & dosage (85) 85
transplantation conditioning - methods (76) 76
fludarabine (73) 73
hematopoietic stem cells (72) 72
oncology (68) 68
stem-cell transplantation (67) 67
versus-host-disease (63) 63
vidarabine - analogs & derivatives (62) 62
pharmacokinetics (61) 61
adolescent (60) 60
hematopoietic stem cell transplantation - methods (60) 60
stem cells (58) 58
aged (57) 57
hematopoietic stem cell transplantation (54) 54
total-body irradiation (50) 50
treatment outcome (50) 50
busulfan - pharmacokinetics (49) 49
transplantation, homologous (49) 49
hematology, oncology and palliative medicine (48) 48
cyclophosphamide (44) 44
young adult (43) 43
acute myeloid-leukemia (42) 42
child (42) 42
retrospective studies (39) 39
conditioning regimen (38) 38
vidarabine - administration & dosage (38) 38
disease-free survival (33) 33
child, preschool (32) 32
analysis (31) 31
busulfan - therapeutic use (31) 31
pharmacology & pharmacy (31) 31
transplantation conditioning (31) 31
hematopoietic stem cell transplantation - adverse effects (30) 30
children (29) 29
recurrence (27) 27
stem cell transplantation (27) 27
article (26) 26
daily iv busulfan (26) 26
dosage and administration (26) 26
hematologic neoplasms - therapy (26) 26
infant (26) 26
mortality (26) 26
survival analysis (26) 26
survival rate (26) 26
cancer (25) 25
health aspects (25) 25
myeloablative agonists - administration & dosage (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
leukemia (24) 24
vidarabine - therapeutic use (24) 24
daily iv-busulfan (23) 23
hematologic malignancies (23) 23
myeloablative agonists - therapeutic use (23) 23
oral busulfan (23) 23
venoocclusive disease (23) 23
acute myelogenous leukemia (22) 22
chemotherapy (22) 22
hepatic venoocclusive disease (22) 22
leukemia, myeloid, acute - therapy (20) 20
busulfan - adverse effects (19) 19
care and treatment (19) 19
toxicity (19) 19
area under curve (18) 18
high-dose busulfan (18) 18
myelodysplastic syndromes - therapy (18) 18
research (18) 18
drug administration schedule (17) 17
preparative regimen (17) 17
unrelated donors (17) 17
graft survival (16) 16
graft vs host disease - prevention & control (16) 16
risk factors (16) 16
therapy (16) 16
dose-response relationship, drug (15) 15
follow-up studies (15) 15
hematopoietic stem cell transplantation - mortality (15) 15
plus cyclophosphamide (15) 15
prospective studies (15) 15
remission induction (15) 15
aml (14) 14
cyclophosphamide - administration & dosage (14) 14
cyclophosphamide - therapeutic use (14) 14
graft vs host disease - etiology (14) 14
medicine & public health (14) 14
methods (14) 14
myelodysplastic syndrome (14) 14
outcomes (14) 14
regimen (14) 14
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2019, Volume 59, Issue 5, pp. 638 - 645
This study aimed to predict the area under the curve (AUC) of the initial busulfan dose using a test dose with the sparse sampling scheme in adult patients who... 
busulfan | HCT | pharmacokinetics | test dose | transplantation | STRATEGY | FLUDARABINE | CHILDREN | SYSTEMIC EXPOSURE | PEDIATRIC-PATIENTS | PHARMACOLOGY & PHARMACY | ORAL BUSULFAN | STEM-CELL TRANSPLANTATION | ASSOCIATION | DAILY IV BUSULFAN | Root-mean-square errors | Intravenous administration | Mean square errors | Pharmacology | Busulfan | Conditioning | Sampling | Bayesian analysis | Patients | Hemopoiesis
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 8, pp. 1424 - 1430
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 10, pp. 1792 - 1800
Highlights • Clofarabine is safe when used with i.v. Bu+Flu in pretransplant conditioning regimens. • Pretransplant conditioning with i.v. Bu+Clo+Flu has... 
Hematology, Oncology and Palliative Medicine | Conditioning regimen | Clofarabine | Fludarabine | Busulfan | Allogeneic stem cell transplantation | TOTAL-BODY IRRADIATION | PREPARATIVE REGIMEN | Allogeneic stem cell | DAILY IV-BUSULFAN | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | IMMUNOLOGY | PLUS CYCLOPHOSPHAMIDE | ADULT ACUTE-LEUKEMIA | HEPATIC VENOOCCLUSIVE DISEASE | transplantation | DECREASED INCIDENCE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Humans | Middle Aged | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Busulfan - administration & dosage | Leukemia, Myeloid, Acute - complications | Young Adult | Myelodysplastic Syndromes - therapy | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Transplantation Conditioning - methods | Child | Graft vs Host Disease - etiology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myeloid, Acute - therapy | Graft Survival | Treatment Outcome | Adenine Nucleotides - therapeutic use | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Myelodysplastic Syndromes - complications | Remission Induction | Arabinonucleosides - therapeutic use | Leukemia, Myeloid, Acute - mortality | Adolescent | Myelodysplastic Syndromes - mortality | Survival Analysis | Care and treatment | Influenza | Cancer | Myelocytic leukemia | Mortality | Stem cells | Nonlymphoid leukemia | Transplantation | Nucleoside analogs
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 2, pp. 265 - 272
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 9, pp. 1381 - 1386
Journal Article
International Journal of Hematology, ISSN 0925-5710, 5/2015, Volume 101, Issue 5, pp. 497 - 504
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 1, pp. 190 - 195
Abstract Conditioning regimens for pediatric acute lymphoblastic leukemia (ALL) usually include total body irradiation (TBI), but TBI may result in serious... 
Hematology, Oncology and Palliative Medicine | Therapeutic drug monitoring | Stem cell transplantation | Fludarabine | Busulfan | Acute lymphoblastic leukemia | TOTAL-BODY IRRADIATION | DAILY IV-BUSULFAN | VENOOCCLUSIVE DISEASE | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | 1ST COMPLETE REMISSION | CONDITIONING REGIMEN | TRANSPLANTATION | CHILDRENS-ONCOLOGY-GROUP | HEMATOLOGY | UNDER-THE-CURVE | HIGH-DOSE ETOPOSIDE | Myeloablative Agonists - therapeutic use | Neutrophils - cytology | Recurrence | Injections, Intravenous | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Humans | Immunosuppressive Agents - therapeutic use | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Graft vs Host Disease - immunology | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Graft vs Host Disease - mortality | Female | Unrelated Donors | Retrospective Studies | Transplantation Conditioning - methods | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Child | Siblings | Drug Administration Schedule | Neutrophils - immunology | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Graft Survival | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Graft vs Host Disease - pathology | Graft vs Host Disease - drug therapy | Survival Analysis | Evaluation | Pediatrics | Medical colleges | Patient outcomes | Mortality | Stem cells | Etoposide | Transplantation | Acute lymphocytic leukemia | Hematopoietic stem cells | Index Medicus
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2011, Volume 17, Issue 3, pp. 412 - 420
We investigated the administration of intravenous (i.v.) busulfan (Bu) combined with melphalan (Mel) in patients with advanced lymphoid malignancies undergoing... 
Hematology, Oncology and Palliative Medicine | Autologous stem cell transplant | Busulfan | Lymphoma | Multiple myeloma | Melphalan | CLINICAL-PHARMACOLOGY | PROGNOSTIC-FACTORS | DAILY IV-BUSULFAN | VENOOCCLUSIVE DISEASE | BONE-MARROW-TRANSPLANTATION | TOXICITY | IMMUNOLOGY | CONDITIONING REGIMEN | TRANSPLANTATION | MULTIPLE-MYELOMA PATIENTS | NON-HODGKINS-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | HEMATOLOGY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents, Alkylating - administration & dosage | Melphalan - therapeutic use | Busulfan - administration & dosage | Lymphoproliferative Disorders - therapy | Young Adult | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Transplantation Conditioning - adverse effects | Lymphoma, Non-Hodgkin - drug therapy | Severity of Illness Index | Busulfan - adverse effects | Busulfan - pharmacokinetics | Busulfan - therapeutic use | Hematopoietic Stem Cell Transplantation | Antineoplastic Agents, Alkylating - pharmacokinetics | Antineoplastic Agents, Alkylating - therapeutic use | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Survival Analysis | Lymphoproliferative Disorders - drug therapy | Aged | Infusions, Intravenous | Antineoplastic Agents, Alkylating - adverse effects | Care and treatment | Mortality | Stem cells | Transplantation | Non-Hodgkin's lymphomas | Health aspects | Cancer
Journal Article